Drug intelligence / Profile preview

NIBRG-14 virosomal H5N1 vaccine

Development stage
Unknown
Lead developer
University of Bergen
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

NIBRG-14 virosomal H5N1 vaccine is an investigational prepandemic **influenza A H5N1 vaccine** produced as a virosomal subunit preparation from the reverse-genetics NIBRG-14 seed virus. NIBRG-14 carries the hemagglutinin and neuraminidase antigens of A/Vietnam/1194/2004 H5N1 on an A/Puerto Rico/8/34 backbone. In a Phase 1 study in healthy adults, two intramuscular doses were evaluated either without adjuvant or with Matrix M, a saponin-based ISCOM adjuvant; Matrix M increased homologous and cross-reactive H5N1 antibody responses and enabled antigen dose sparing. ([researchportal.ukhsa.gov.uk](https://researchportal.ukhsa.gov.uk/en/publications/evaluation-of-a-virosomal-h5n1-vaccine-formulated-with-matrix-m-a/))

Other names
H5N1 virosomal vaccineH-5N1 virosomal vaccineH 5N1 virosomal vaccineMatrix M-adjuvanted virosomal H5N1 vaccineNIBRG-14 virosomal vaccineNIBRG14 virosomal vaccineNIBRG 14 virosomal vaccine
02

Targets

NeuraminidaseHA (Hemagglutinin)

Beyond the preview

Go deeper on NIBRG-14 virosomal H5N1 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIBRG-14 virosomal H5N1 vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call